How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

Recursive Superintelligence has raised $650 million at a $4.65 billion valuation in a funding round led by GV and Greycroft, according to the company. The round also included participation from AMD ...

AT a time when professional philosophers are trying to persuade us that philosophy is an attempt to answer questions which should never have been asked, and professional scientists are taking over the ...

This has been implicit in various points I’ve made in recent Editors’ Blog posts. I want to make it more explicit. What’s occupying Donald Trump’s time right now? The big items are the Ballroom, the ...